Filtered By:
Cancer: Glioma

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 625 results found since Jan 2013.

Lentivirus vector ‑mediated genetic manipulation of oncogenic pathways induces tumor formation in rabbit brain
Mol Med Rep. 2021 Jun;23(6):422. doi: 10.3892/mmr.2021.12061. Epub 2021 Apr 13.ABSTRACTTranslation of promising experimental therapies from rodent models to clinical success has been complicated as the novel therapies often fail in clinical trials. Existing rodent glioma models generally do not allow for preclinical evaluation of the efficiency of novel therapies in combination with surgical resection. Therefore, the aim of the present study was to develop a larger animal model utilizing lentivirus vector‑mediated oncogenic transformation in the rabbit brain. Lentiviruses carrying constitutively active AKT and H‑Ras on...
Source: Molecular Medicine Reports - April 13, 2021 Category: Molecular Biology Authors: Farizan Ahmad Anna Hyv ärinen Agnieszka Pirinen Venla Olsson Jaana Rummukainen Arto Immonen Johanna N ärväinen Pasi Tuunanen Timo Liimatainen Virve K ärkkäinen Jari Koistinaho Seppo Yl ä-Ηerttuala Source Type: research

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
Oncotarget. 2021 Mar 2;12(5):401-411. doi: 10.18632/oncotarget.27884. eCollection 2021 Mar 2.ABSTRACTThe glioma associated oncogene-1 (GLI1), a downstream effector of the embryonic Hedgehog pathway, was detected in chronic lymphocytic leukemia (CLL), but not normal adult cells. GLI1 activating mutations were identified in 10% of patients with CLL. However, what induces GLI1 expression in GLI1-unmutated CLL cells is unknown. Because signal transducer and activator of transcription 3 (STAT3) is constitutively activated in CLL cells and sequence analysis detected putative STAT3-binding sites in the GLI1 gene promoter, we hypo...
Source: Oncotarget - March 22, 2021 Category: Cancer & Oncology Authors: Uri Rozovski David M Harris Ping Li Zhiming Liu Preetesh Jain Taghi Manshouri Ivo Veletic Alessandra Ferrajoli Prithviraj Bose Phillip Thompson Nitin Jain Srdan Verstovsek William Wierda Michael J Keating Zeev Estrov Source Type: research

Research Articles A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma
Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of the lack of precision therapies and limited therapeutic access to intracranial tumor sites due to the presence of the blood-brain and blood-tumor barriers. We have developed a precision medicine approach for GBM treatment that involves the use of brain-penetrant RNA interference–based spherical nucleic acids (SNAs), which consist of gold nanoparticle cores covalently conjugated with radially oriented and densely packed small interfering RNA (siRNA) oligonucleotides. On the basis of previous preclinical evaluation, we cond...
Source: Science Translational Medicine - March 10, 2021 Category: Biomedical Science Authors: Kumthekar, P., Ko, C. H., Paunesku, T., Dixit, K., Sonabend, A. M., Bloch, O., Tate, M., Schwartz, M., Zuckerman, L., Lezon, R., Lukas, R. V., Jovanovic, B., McCortney, K., Colman, H., Chen, S., Lai, B., Antipova, O., Deng, J., Li, L., Tommasini-Ghelfi, S Tags: Research Articles Source Type: research

Cancers, Vol. 13, Pages 944: Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma
wn Spencer J. Collis Brain tumours kill more children and adults under 40 than any other cancer, with approximately half of primary brain tumours being diagnosed as high-grade malignancies known as glioblastomas. Despite de-bulking surgery combined with chemo-/radiotherapy regimens, the mean survival for these patients is only around 15 months, with less than 10% surviving over 5 years. This dismal prognosis highlights the urgent need to develop novel agents to improve the treatment of these tumours. To address this need, we carried out a human kinome siRNA screen to identify potential drug targets that augment the e...
Source: Cancers - February 24, 2021 Category: Cancer & Oncology Authors: Natasha Carmell Ola Rominiyi Katie N. Myers Connor McGarrity-Cottrell Aurelie Vanderlinden Nikita Lad Eva Perroux-David Sherif F. El-Khamisy Malee Fernando Katherine G. Finegan Stephen Brown Spencer J. Collis Tags: Article Source Type: research

Molecules, Vol. 26, Pages 901: Silencing ZEB2 Induces Apoptosis and Reduces Viability in Glioblastoma Cell Lines
Conclusions: In line with previous investigations, our results indicated a critical oncogenic role for ZEB2 overexpression in brain glioma tumors. These properties make ZEB2 an essential molecule for further studies in the treatment of glioma cancer.
Source: Molecules - February 9, 2021 Category: Chemistry Authors: Sahar Safaee Masoumeh Fardi Nima Hemmat Neda Khosravi Afshin Derakhshani Nicola Silvestris Behzad Baradaran Tags: Article Source Type: research

MicroRNA ‑186‑5p downregulation inhibits osteoarthritis development by targeting MAPK1.
In conclusion, the present results indicated that miR‑186‑5p could attenuate IL‑1β‑induced chondrocyte inflammation damage by increasing MAPK1 expression, suggesting that miR‑186‑5p may be used as a potential therapeutic target for OA. PMID: 33537828 [PubMed - in process]
Source: Molecular Medicine - February 6, 2021 Category: Molecular Biology Authors: Li Q, Wu M, Fang G, Li K, Cui W, Li L, Li X, Wang J, Cang Y Tags: Mol Med Rep Source Type: research

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
In this research, we analyze a relationship between CD44 expression and responsiveness to Bev and elucidate the role of CD44 in anti ‐VEGF therapy. These results indicate CD44 will be a useful biomarker for predicting responsiveness to bevacizumab and may serve as a therapeutic target in both primary and recurrent GBMs. AbstractAntiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev therapy....
Source: Cancer Medicine - February 5, 2021 Category: Cancer & Oncology Authors: Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Shohei Kohno, Shiro Ohue, Saya Ozaki, Shirabe Matsumoto, Satoshi Suehiro, Yawara Nakamura, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Tags: ORIGINAL RESEARCH Source Type: research